key: cord-1053648-vfhwtke1
authors: Buonfrate, Dora; Chesini, Fabio; Martini, Davide; Roncaglioni, Maria Carla; Fernandez, Maria Luisa Ojeda; Alvisi, Maria Francesca; De Simone, Irene; Rulli, Eliana; Nobili, Alessandro; Casalini, Giacomo; Antinori, Spinello; Gobbi, Marco; Campoli, Caterina; Deiana, Michela; Pomari, Elena; Lunardi, Gianluigi; Tessari, Roberto; Bisoffi, Zeno
title: High dose ivermectin for the early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof of concept clinical trial
date: 2022-01-06
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2021.106516
sha: be1039cf9d7e1c9ea1936545d1254aeee338c43f
doc_id: 1053648
cord_uid: vfhwtke1

High concentrations of ivermectin demonstrated antiviral activity against SARS-CoV-2 in vitro. Aim of this study was to assess safety and efficacy of high-dose ivermectin in reducing viral load in individuals with early SARS-CoV-2 infection. Randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial. Participants: adults recently diagnosed with asymptomatic/oligosymptomatic SARS-CoV-2 infection, providing informed consent. Exclusion criteria: pregnant or lactating women; CNS diseases; dialysis; severe medical condition with prognosis < 6 months; warfarin treatment; antiviral/chloroquine phosphate/hydroxychloroquine treatment. Participants were assigned according to a randomized permuted block procedure to one of the following arms with allocation ratio 1:1:1: placebo (arm A); single dose ivermectin 600 μg/kg plus placebo for 5 days (arm B); single dose ivermectin 1200 μg/kg for 5 days (arm C). Primary outcomes: serious adverse drug reactions (SADR) and change of viral load at Day 7. From 31th July, 2020 to 26th May, 2021, 32 participants were randomized to arm A, 29 to arm B and 32 to arm C. The recruitment was stopped on 10th June, because of a dramatic drop of cases. Eighty-nine participants were included in the safety analysis set, the change in viral load was calculated on 87 participants. No SADR were registered. The mean log10 viral load reduction was 2.9 in arm C (SD 1.6), 2.5 (2.2) in arm B and 2.0 (2.1) in arm A, with no significant differences (p=0.099 and 0.122 for C versus A and B versus A, respectively). High-dose ivermectin was safe, but did not prove efficacy to reduce viral load.

The vaccination roll-out has certainly had a key role in the fight against COVID-19. Nevertheless, emergence of SARS-CoV-2 variants and the (slow) pace of vaccination hampered the expected drop in cases in most parts of the world [1, 2] . Thus, the pandemic is still hitting hard, and antiviral drugs, preferably at low cost and widely available, are still badly needed.

At first, research has been oriented towards drug repurposing, which is time-saving compared to new drug discovery [3] . Several compounds have been tested against SARS-CoV-2 in vitro and subsequently in vivo, including drugs not primarily used as antiviral agents. In particular, chloroquine/hydroxychloroquine and ivermectin were of interest for use also in low-and middle-income (LMIC), as these drugs are widely available (for treatment of parasitic infections), and inexpensive [3] . Therefore, although recent evidence has globally shifted the attention towards novel (and much more expensive) ad hoc medications [4] [5] [6] [7] , interest about a possible role for cheaper and older compounds remains.

In March 2020, Australian researchers demonstrated that ivermectin, a drug used for decades to combat parasitic infections, had antiviral activity against SARS-CoV-2 in Vero cell cultures, virtually zeroing the viral load in 48 hours [8] . This sparked considerable interest in this "old" drug as a potential cure for COVID-19, resulting on one hand in a consistent number of clinical trials testing ivermectin efficacy, on the other in an uncontrolled procurement of the drug for self-treatment [9] . However, a plasma concentration of ivermectin compatible with the IC-50 found in vitro (approximately 2.5 µM, equivalent to 2,190 ng/mL) is far from being achievable with the usual doses of this drug [10] (40-80 ng/mL after 200-400 µg/kg). Based on this, we would expect ivermectin to show neither clinical nor virological efficacy against COVID-19 unless higher doses are administered.

The aim of this study was to assess the efficacy and safety of high doses of ivermectin (namely: one arm with 600 and another with 1200 µg/Kg dose, for five consecutive days) for the treatment of SARS-CoV-2 infection. The doses were chosen based on the following considerations: i) according with the reported PK profile in plasma [11, 12] , it can be supposed that repeated daily administrations result in drug accumulation, with predicted plasmatic levels only slightly higher than those observed with single administration of 2000 μg/kg in fasted state (248 ng/mL), which were well tolerated [11] . ii) Studies in mammals [13, 14] showed much higher ivermectin levels in pulmonary tissue than in plasma.

Primary objectives of this study were to define if: 1) ivermectin, administered at two different high dosages is safe in participants with initial, asymptomatic or oligosymptomatic SARS-CoV-2 infection, 2) ivermectin, administered at the dosage(s) found to be safe, decreases the viral load of SARS-CoV-2 at Day 7.

COVER was a randomised, investigator-initiated, double-blind, multicentre, phase II, dose-finding, proof of concept clinical trial carried out in outpatients consecutively diagnosed in four sites in Italy. The study protocol (available as Supplementary File) was approved by the national Ethics Committee of INMI -Spallanzani in Rome that is competent for all COVID-19 trials in Italy (resolution 139/2020 of 28 th May, 2020), and by the Italian drug agency AIFA (resolution 136BIS/2020 of 18 th May, 2020). The protocol was also registered with ClinicalTrials.gov, NCT04438850.The study complied with the Declaration of Helsinki and was done in accordance with Good Clinical Practice guidelines. All participants provided written informed consent.

Participants were adult (≥18 years) subjects newly diagnosed with SARS-CoV-2 infection with a Real-Time PCR analysis of nasopharyngeal swabs, not requiring hospitalization or oxygen supplementation (COVID-19 severity score < 3 [15] ), and providing their informed consent to the study. The main exclusion criteria were: pregnant or lactating women; known Central Nervous System disease; participants under dialysis; any severe medical condition with a prognosis of < 6 months; warfarin treatment; antiviral treatment; chloroquine phosphate or hydroxychloroquine treatment.

Study arms were: placebo arm (arm A); Single dose ivermectin 600 μg/kg plus placebo for 5 days (arm B); single dose ivermectin 1200 μg/kg for 5 days (arm C).

Participants were randomly assigned by a centralized computer system to one of the three arms with an allocation ratio 1:1:1. The study biostatistician prepared the sequence of treatments, generated using SAS 9.4 release, according to a randomized permuted blocks procedure. The treatment ID was obtained through REDcap, used as web-based Clinical Data Management System for the study. After randomization, the treatment ID and the patient's weight were communicated to the hospital pharmacist who was in charge to prepare the study treatment according to the randomization list. In order to keep investigators and participants blinded, the number of tablets to be administered was the same, irrespective of the study arm in which the participant was randomized. Placebo tablets were identical in appearance and taste to ivermectin.

Also, the staff in charge of the laboratory analyses were blinded.

After randomization, participants were provided the daily therapy in five packs, numbered 1 to 5 with the respective dates and labelled with the randomization code. The division into single doses and the labelling were done by the study pharmacists under controlled conditions. The daily doses were self-administered on an empty stomach with water.

Starting with Day 1 (day of first dose), investigators contacted the participants daily by phone until Day 5, in order to check for the correct uptake of the drug and for the occurrence of any adverse event (AE), based on a pre-specified list. At Day 7, the participant was re-assessed with an in-person visit, a nasopharyngeal swab was performed and examined locally with RT-PCR, then stored at -80 °C until the final (centralised) analysis. Full blood count and transaminases were also checked locally. Further onsite visits were scheduled on Day 14 (in all similar to Day 7) and Day 30 (final follow-up visit). Nasopharyngeal swabs were performed if positive at previous visit and the left-over material was stored as above. Unscheduled visits for any reason were also foreseen. Participants were provided with a dedicated phone number so that they could contact the Investigators in case of need.

Adverse events (AEs) were assessed for severity according to NCI-CTCAE grading version 4.03, and causal relation to the study treatment or to SARS-CoV-2 infection was established by the study physician and recorded in the eCRF.

Serious adverse events or reactions (SAE/SADR) had to be immediately (not later than 24 hours) reported to the Sponsor as well as to the Study Safety Desk. The same applied to serious unexpected adverse reactions (SUSAR). 

The statistical study design was conceived in 2 steps:

The step 1 aimed at testing the safety of the two experimental arms in terms of SADR occurrence, on the first 60 evaluable participants (20 per arm). If the experimental arm failed to demonstrate as safe, the allocation of participants was planned to be interrupted. At the same time, interim analyses on efficacy and futility were planned comparing control and experimental arms. Futility and efficacy criteria for prematurely stopping the trial are detailed in the study protocol.

The step 2 aimed at testing the efficacy of experimental arms, considered safe at first stage, comparing to the control arm in terms of viral load decrease.

The primary safety endpoint was the occurrence of a SADR. According to A'Hern [16] single stage design, setting a type I error rate of 10% and power of 80% and hypothesizing that the true toxicity rate (SADRs) was 5%, 20 participants, in each experimental arm, were needed to test the null hypothesis that the toxicity rate was 30% against a one-sided alternative.

Primary efficacy endpoint was the difference in viral load decline from baseline to 7 days. Viral load was measured as log 10 of genome copies per µL, ascertained by Droplet Digital quantitative PCR (dd-PCR) [17, 18] . To et al [19] reported a difference in mean viral load decline of 1.05 log 10 copies (SD=0.69 log 10 copies). The desired difference in decrease between each experimental group and control was at least 0.47 log 10 copies per mL (effect size Δ =0.68, considered to be of moderate-large magnitude according to Cohen

[20]). According to these hypotheses, with 34 pts per arm the study had a power=80% to detect a difference between control and experimental arms, at 0.025 alpha level, one side. Therefore, if both experimental treatments proceeded to step 2 and were compared with the control group, the total number of participants to be analysed had to be 102. Considering a potential 20% loss to follow-up, including missing or inadequate specimens, it was planned to enrol 129 participants.

Data were analysed according to the Statistical Analysis Plan (Supplementary material) using the software SAS 9.4 release. The primary safety analysis was performed on safety analysis set, including participants who received at least one dose of study treatment.

The analysis of primary efficacy endpoint was performed on the evaluable analysis set, considering all participants as originally assigned to the treatment arms, without major violations of eligibility criteria and having the viral load evaluable at Day 7.

A per-protocol (PP) analysis set was defined including only participants who took the allocated treatment as specified in the protocol for 5 days, in order to check for consistency with the primary analysis.

The proportion of participants in each experimental group experiencing at least one SADR was described by means of frequency and percentages.

The mean of the differences in viral load decline from baseline to Day 7 between each experimental group and the control group was described by standard summary measures for continuous data and compared by mean of Student T test and Wilcoxon test (according to Shapiro-Wilk test for normality).

A full description of the statistical analyses of all secondary outcomes is reported in the statistical analysis plan (Supplementary material). The assessment of tolerability profile was mainly based on adverse drug reactions (ADRs) and the frequency and nature of SAEs. The proportion of participants in each group experiencing adverse events was compared through the chi-square test (or Fisher's exact test when appropriate). Generalized longitudinal mixed models were used to analyse the trend over time of viral load at the different time points. Time to clinical resolution (TCR) was calculated as the time from randomization to clinical resolution or death. TCR was analysed with Cox regression models and describe by Kaplan Meier method. The proportion of participants with virological clearance was described by frequencies and proportions with their relative exact 95% CI. Chi-squared test was used to test the proportion of participants with virological clearance at day 14 and Fisher's exact test was used at day 30.

The measurement of the plasma concentrations of ivermectin was included as an ancillary study to inform on the maximal drug levels and the drug accumulation following repeated doses, on the inter-individual variability and, possibly, on association between blood drug concentration and clinical endpoints. In fact, a high variability in absorption had been described [11] . The peak plasma concentrations (Cmax) are observed at approximately four hours after dosing, with an elimination half-life of 18-35 hours [11, 12] . For these reasons and for feasibility considerations, it was planned to collect blood samples in a subset of participants at three time-points: just before, four and 48 hours after the fifth dose. Plasma aliquots were stored at -20°C (or lower T) until analysis.

Ivermectin was measured by HPLC-MS/MS at the laboratory of the IRCCS-Sacro Cuore Don Calabria hospital, with a method validated according to the EMA guidelines. Details on the procedure are reported in the study protocol.

The Sponsor was IRCCS Sacro Cuore Don Calabria hospital, which received funds for this trial from the Italian Ministry of Health in the framework of "Ricerca corrente". Tablets of 9 mg ivermectin and of placebo were donated by Insud Pharma, Madrid. The funders had no role in study designs, data collection, data analysis, data interpretation, or writing of the report. Table 1 ). This information was provided by all centres but one (Rovereto, which contributed with 2 randomized participants). Among the other centres, 845 participants were screened and 91 (10.8%) were randomized. The main reasons for exclusion were: infection not recent (56.9%), patient refusal (15.4%), severity score >2 (7.8%), organizational reasons (7.2%). Ninety-three participants were randomly assigned to the treatment arms. Four never started the treatment and withdrew the consent, the other eighty-nine participants received at least on day of study treatment and therefore they were included in the analysis of the primary endpoints. Two (one in arm A and one in arm C) had a missing sample for the viral load at day 7, therefore 87 participants (93.5%) were included in the primary endpoint for efficacy. Seventy-five participants (84.3%) received 5 days of treatment and were included in the PP analysis set.

Baseline population. Main baseline demographic and clinical characteristics of the study population are summarized in Table 1 for all randomized participants and in Supplementary Table 2 Comorbidities were reported by one third of the participants. Eighty (86%) participants were symptomatic with a median duration of 4 days, cough being the most frequent symptom, followed by fever and fatigue.

The severity score was 1 for 78 participants (84%), and 2 for 15 (16%).

Details of main physical findings, baseline laboratory exams and concomitant treatments are summarized in Supplementary Tables 3, 4 and 5.

Summary of treatment compliance is reported in Table 2 . Fourteen participants (4.3%) discontinued the treatment: 1 (3.1%) in arm A, 2 (6.9%) in arm B and 11 (34.4%) in arm C. The interruptions in arm C were all due to tolerability. Seven participants received only one day of treatment, three received two and three days, respectively, and one received four days (Supplementary Table 6 ).

No SADRs were observed in any of the study groups. Results on the viral load (Log10) at day 7 versus baseline, are summarized in Table 3 . In arm C, the mean reduction of the viral load was 2.9 (SD 1. As an exploratory analysis, the same proportion for day 7 was also added. No significant difference between arms was observed in any of the time points. The hospitalization rate was 3/30 (10.0%) for Arm C, 1/29 (3.6%) for Arm B and 0 for Arm A. Regarding the COVID-19 severity score, at Day 14 all participants had a score of 1, except for two participants in arm B with a severity score of 2 and 3. At Day 30 all participants had a severity score of 1. 

This was the study with the highest dose of ivermectin ever used in a clinical trial for the treatment of COVID-19, or, indeed, for any other condition. The higher dosage (1200 µg/kg for 5 days) showed no safety concerns, as no SADRs were observed. The co-primary efficacy outcome was the reduction in viral load on day 7. The reduction (expressed in Log10) was 2.9 for the higher dose (I-1200), 2.5 for the lower dose (I-600) and 2.0 for placebo, but the differences were not statistically significant. No significant differences were observed in the clinical outcome, either, although the study was not powered sufficiently to detect differences in the secondary outcomes. Concerning adverse events, 3 out of the 4 SAEs (hospitalization for worsening of the disease) reported were in the I-1200 arm, and 1 in the I-600 arm.

Mild or moderate AE were numerous and reported in all three groups, with the highest proportion in the I-1200 arm. Out of 14 treatment interruptions, 12 were due, precisely, to side effects, of which 11 were in the high-dose arm.

The rationale for using a very high dosage was based on the in vitro study published by Caly and colleagues [8] . The foreseeable plasma concentration after the fifth day of treatment made effective drug levels in pneumocytes plausible, also considering that much higher levels are likely to be achieved in pneumocytes than in plasma [21] . The dosages used in our study were selected according to the pharmacokinetics considerations reported in the study protocol and in the Introduction: the maximal plasma concentration (Cmax) after the 5 th dose should be of the same order as after a single dose of 2 mg/kg, already found safe in healthy volunteers [11] . Our PK results, albeit on a limited number of participants, confirmed our initial hypotheses, indeed showing slightly higher concentrations than foreseen, and reaffirm the biological plausibility of high-dose ivermectin for COVID-19. However, our study failed to show a significant effect on viral load decline.

This study confirms that ivermectin at high dose can be considered safe. However, a high proportion of dropouts, albeit for mild or moderate side effects, was observed in the high-dose treatment arm. It is true that symptomatic subjects at greater risk of illness progression might be more motivated to continue a treatment in presence of minor side effects. However, other considerations make a new trial on high-dose ivermectin problematic. First of all, no signal of a possible positive clinical outcome was highlighted. On the contrary, the 4 participants whose disease worsened enough to cause hospitalization were all in the treatment arms, and 3 of these in the high-dose arm. Although this is an observation, rather than a statisitically valid conclusion,, it might be questioned whether ivermectin itself could have at least partly contributed to the clinical worsening. Indeed, there are concerns due to its mechanism of action which is not direct against the virus but implies inhibition of a host protein involved in intracellular transport [22] . However, the clinical features of the hospitalized participants here were deemed compatible with COVID-19 evolution, and no major neurological signs were observed, as reported previously in cases of serious ivermectin toxicity [23]. Different groups have carried out systematic reviews with meta-analysis on the use of ivermectin for COVID-19 [26] [27] [28] [29] . Results between different works are inconsistent, and the quality of clinical trials included in some reviews has been questioned. On one hand, fraudulent data have been detected; on the other, the sample size of many trials was too small or the study quality was assessed as low [28, 30] .

Amongst other reviews, a Cochrane meta-analysis has been published [28] . It analysed 14 randomized trials with ivermectin for COVID-19 published until May 26, 2021 including a total of 1678 participants, finding no evidence favouring ivermectin for clinical outcomes, nor for viral clearance. In all studies the dosage used was much lower than that of our lower dosage arm, with the exception of the study by A. Krolewiecki et al. in Argentina [31] , which used the same dose as our I-600 arm. The latter study showed a reduction in viral load in treated subjects versus controls, in a subgroup of participants in whom the plasma concentration of the drug, measured four hours after dosing, exceeded 160 ng/mL.

Our study has some limitations. The first is that it failed to reach the planned sample size. However, the Conditional Power (cp) Analysis showed that, even reaching the target sample size, the hypothesized effect would hardly be demonstrated (Arm B vs. A cp=0.001, Arm C vs. A cp=0.27). Another limitation was the extreme difficulty of recruiting participants. About 90% of subjects screened were not eligible to be included, for various reasons, including a high proportion of refusal to give their consent. Moreover, 76 out of the 93 study participants (84%) were recruited by the coordinating site. Major strengths of this study were the double-blind design, the inclusion of a placebo arm, and the lack of any other major deviations from the study protocol.

In conclusion, we did not demonstrate a significant reduction in viral load between ivermectin and placebo, although a trend for the highest dose is apparent. Whether this drug might have clinical efficacy at lower doses remains debated. We believe that our findings further support the recommendation of the WHO[25], suggesting that it is currently advisable to refrain from administrating ivermectin for the treatment of COVID-19 outside clinical trials. Considering the reduced tolerability, large, high-dose clinical trials should not be recommended. -Reason for never started -n (%) 

COVID vaccines slash viral spread -but Delta is an unknown

What constitutes success in the roll-out of COVID-19 vaccines?

Drug repurposing approach to fight COVID-19

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. The New England journal of medicine

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. The New England journal of medicine 2021

Antiviral pills could change pandemic's course

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Latin America's embrace of an unproven COVID treatment is hindering drug trials

Standard Dose Ivermectin for COVID-19

Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects

Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers

Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat

Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle

Endpoints for randomized controlled clinical trials for COVID-19 treatments

Sample size tables for exact single-stage phase II designs

Assessment of the direct 27

Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines

Ivermectin for preventing and treating COVID-19. The Cochrane database of systematic reviews

Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials

The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable

Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial

We acknowledge the DSMB members for their enthusiastic and highly professional support: Piero Olliaro, Simone Accordini, Cristiano Chiamulera.

Funding: We warmly thank InsudPharma & Mundo Sano for the donation of study medication (Ivermectin and Placebo), and Alpine Lions Cooperation for the contribution. The study was partly funded by the Italian Ministry of Health "Fondi Ricerca Corrente" to IRCCS Sacro Cuore Don Calabria Hospital.

Ethical Approval: The protocol received clearance from the Ethics Committee of INMI -Spallanzani in Rome that is competent for all COVID-19 trials in Italy (resolution 139/2020 of 28th May, 2020)